Medovate’s game-changing SAFIRA® (SAFer Injection for Regional Anesthesia) has been featured in the Journal of Anaesthesia Practice.
The article, written by Dr Stewart Southey, looks at how the COVID-19 pandemic has challenged the very nature of anaesthesia services, and the need for increased attention on patient safety in regional anaesthesia.
Dr Southey explains how there is evidence that Aerosol Generating Procedures (AGP), such as tracheal intubation, increase the odds of transmission of acute respiratory infection 6.6 times compared with those who are not exposed and that postoperative pulmonary complications after elective surgery in COVID-positive patients is significantly higher.
This is supported in a recent joint statement from the American Society of Regional Anesthesia and Pain Medicine (ASRA) and European Society of Regional Anaesthesia and Pain Therapy (ESRA) which states Regional Anaesthesia (RA) rather than General Anaesthesia (GA) has been advocated.
Dr Southey highlights SAFIRA® as offering a pioneering solution.
He comments: “A device recently launched by a UK-based company, Medovate, (SAFIRA®: SAFer Injection for Regional Anesthesia) may be an interesting safety addition given that it enables RA to become a single operator process, with the assistant able to maintain a safe distance. The device has European CE Mark approval and makes use of a foot operator which controls a syringe driver to either aspirate or inject the local anaesthetic drug.”
Click here to read the article in full: "Providing safe regional anaesthesia during the COVID-19 pandemic"
*** *** *** *** ***
More about SAFIRA® here